Clinical trial
A PHASE 3 STUDY OF TOLERABILITY, SAFETY, AND EFFICACY, OF DMT310 IN PATIENTS WITH ACNE VULGARIS
NCT06090721 is registered in ClinicalTrials.gov with Dermata Therapeutics as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A PHASE 3 STUDY OF TOLERABILITY, SAFETY, AND EFFICACY, OF DMT310 IN PATIENTS WITH ACNE VULGARIS
- Lead sponsor
- Dermata Therapeutics
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- December 8, 2023
- Completion date
- April 30, 2025
- Enrollment
- 520 (actual)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.